What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future?

Q4 Immunology and Microbiology

Clinical and Experimental Neuroimmunology Pub Date : 2023-10-08 DOI:10.1111/cen3.12769

Cavid Baba, Ipek Yavas, Ulvi Samadzade, Asiye Tuba Ozdogar, Serkan Ozakbas

{"title":"What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future?","authors":"Cavid Baba, Ipek Yavas, Ulvi Samadzade, Asiye Tuba Ozdogar, Serkan Ozakbas","doi":"10.1111/cen3.12769","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The study aimed to examine the demographic, clinical and therapeutic characteristics of people with neuromyelitis optica spectrum disorders (NMOSD, pwNMOSD) during the coronavirus disease 2019 (COVID-19) pandemic.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was an observational study of pwNMOSD at a tertiary care clinic. Data on COVID-19 infection were collected between 11 March 2020 and 30 April 2022. Data on COVID-19 symptoms, severity and death rate were analyzed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We observed 16 confirmed COVID-19 cases and three suspected cases. Three (15.8%) patients had severe infections, whereas 16 (84.2%) had mild conditions. Only one person was admitted to the hospital due to pneumonia. COVID-19 re-infection was reported by three patients. No pwNMOSD died as a result of COVID-19 disease. Cough was the most frequently reported symptom. The incidence of COVID-19 infection in our cohort was 21.1%. Immunosuppressants were taken by 57.9% of pwNMOSD with COVID-19, and by 84.5% of pwNMOSD without COVID-19.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Due to the small sample size, there was no predominant difference in infection between infected and uninfected patients with or without immunosuppressant drugs. However, given that immunosuppressants are a risk for infection, patient decision-making in their selection is important.</p>\n </section>\n </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The study aimed to examine the demographic, clinical and therapeutic characteristics of people with neuromyelitis optica spectrum disorders (NMOSD, pwNMOSD) during the coronavirus disease 2019 (COVID-19) pandemic.

Methods

This was an observational study of pwNMOSD at a tertiary care clinic. Data on COVID-19 infection were collected between 11 March 2020 and 30 April 2022. Data on COVID-19 symptoms, severity and death rate were analyzed.

Results

We observed 16 confirmed COVID-19 cases and three suspected cases. Three (15.8%) patients had severe infections, whereas 16 (84.2%) had mild conditions. Only one person was admitted to the hospital due to pneumonia. COVID-19 re-infection was reported by three patients. No pwNMOSD died as a result of COVID-19 disease. Cough was the most frequently reported symptom. The incidence of COVID-19 infection in our cohort was 21.1%. Immunosuppressants were taken by 57.9% of pwNMOSD with COVID-19, and by 84.5% of pwNMOSD without COVID-19.

Conclusions

Due to the small sample size, there was no predominant difference in infection between infected and uninfected patients with or without immunosuppressant drugs. However, given that immunosuppressants are a risk for infection, patient decision-making in their selection is important.

查看原文本刊更多论文

COVID-19 大流行对神经脊髓炎视网膜频谱障碍患者的未来有何启示？

目的本研究旨在探讨 2019 年冠状病毒病（COVID-19）大流行期间神经脊髓炎视网膜频谱障碍（NMOSD，pwNMOSD）患者的人口统计学、临床和治疗特征。方法这是一项针对一家三级医疗诊所的 pwNMOSD 的观察性研究。在 2020 年 3 月 11 日至 2022 年 4 月 30 日期间收集了 COVID-19 感染数据。对 COVID-19 的症状、严重程度和死亡率进行了分析。结果我们观察到16例COVID-19确诊病例和3例疑似病例。3名患者（15.8%）感染严重，16名患者（84.2%）感染轻微。只有一人因肺炎入院。有 3 名患者报告再次感染 COVID-19。没有人因感染 COVID-19 而死亡。咳嗽是最常报告的症状。在我们的队列中，COVID-19感染的发病率为21.1%。57.9% 患有 COVID-19 的 pwNMOSD 和 84.5% 未患 COVID-19 的 pwNMOSD 都服用了免疫抑制剂。结论由于样本量较小，服用或未服用免疫抑制剂的感染者与非感染者在感染方面没有明显差异。不过，鉴于免疫抑制剂存在感染风险，患者在选择免疫抑制剂时的决策非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Neuroimmunology Immunology and Microbiology-Immunology and Microbiology (miscellaneous)

CiteScore

1.60

自引率

0.00%

发文量